The entries of “Technologies made in Vienna” are displayed in the project language.
Technologies from Vienna
Center for Biomarker Research in Medicine (CBmed) GmbH
Customized Solutions for Biomarker ResearchThe focus of CBmed is on providing CBsolutions, “Customized Solutions for Biomarker Research”.
CBmed, an Austrian funded K1 competence center, links excellent research infrastructure, scientific expertise, medical knowledge, national and international industry partners for systematic medical biomarker research.
CBmed brings together scientific experts with leading pharmaceutical, diagnostic, medical-technology and IT industry partners. In addition, CBmed has a strong network in the area of Biobanking including the largest Biobank in Europe, Biobank Graz, and the European Biobanking network BBMRI-ERIC. CBmed research projects will identify new biomarkers, validate potential biomarkers and conduct translational biomarker research for products to be used in clinical practice.
CBmed will develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.
Our vision is to become the world's most recognized center for biomarker research in personalized medicine by 2030.
This will be achieved by integrating cutting-edge technologies with international and interdisciplinary expertise in the fields of cancer, metabolism and inflammation.
Together with our scientific and industry partners, we will develop solutions and products for patient care and cure.
CBmed RESOURCESCBmed links excellent research infrastructure, scientific expertise, medical knowledge, national and international industry partners for systematic medical biomarker research.
AlleinstellungsmerkmalCBmed GmbH represents a unique one-stop shop providing an integration of state-of-the-art core lab technologies combined with scientific and medical expertise throughout the full cycle of clinical biomarker discovery, validation and translation, at the public-private partnership interface.
MetabolomicsThe metabolome is especially well suited for biomarker research as the most integrated, dynamic and nearest-to-the-phenotype measure. Metabolomics offers important information in the development of pro- gnostic and predictive biomarkers since metabolites are directly influenced by genetic, transcriptomic, proteomic, environmental factors and their complex interactions.
AlleinstellungsmerkmalOur metabolomics expertise is focused on early biomarker discovery and includes intrinsic quality control and a focus on the elucidation of mechanistic insight. CBmed Metabolomics expertise ranges from basic research to preclinical testing and clinical research, representing a one-stop-shop of custom-tailored metabolomics modules for cooperative, interactive research.
Next-Generation Sequencing (NGS) in Genetics & GenomicsNGS provides powerful insights into genetic mutations and molecular networks under lying disease for a broad set of genes. NGS technologies will revolutionize a number of areas in clinical practice, including the validation and analysis of sequencingbased bio markers, a tool increasingly relevant for diagnosis in multiple disease areas and for the selection and monitoring of therapeutic treatments.
AlleinstellungsmerkmalWe are developing complete "sample-to-insight" workflows under highest quality standards and control workflows for diagnostic NGS, including pre-analytics for NGS-based biomarker discovery in clinical discovery, translation and routine.
Immunology & FACSThe immune system is one of the most complex systems in the human body involved in almost all disease patterns. High-throughput methods enable the assessment of chan- ges in protein patterns of immune cells that are relevant for disease related diagnosis, prognosis and prediction. We provide immunophenotyping expertise ranging from diagnostic, prognostic and predictive biomarkers for immune defects to highly standardised methods for cell biology analyses and immune signature discovery.
AlleinstellungsmerkmalOur wide expertise covers basic research, preclinical and clinical studies in close cooperation with large Austrian clinical institutions in Graz and Vienna, involving patient recruitment defined by customer needs through a one-stop solution from patient recruitment to professional data management and analysis in an integrated high-quality custom workflow.
Digital Pathology / ImagingOur research is focussed on applying multiplex IHC and multispectral imaging techno- logies with novel analytical tools to enable the use of the immune cell population as a prognostic and predictive biomarker.
AlleinstellungsmerkmalCBmed offers solutions from cohort design and assembly to pathological analysis,
Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), image ana- lysis and other complimentary analyses.
Proteomics & In vivo ImagingWe aim to bridge proteomics in molecular pathology with functional in-vivo imaging techniques to de ne novel targets and obtain novel biomarkers dependent on the respec- tive tumor entity for clinical application. Therefore, a complete and integrated work ow from target identi cation to probe development and correlation of in-vivo location with histopathological analysis is implemented. Tumor biomarkers are investigated by whole proteome platforms for development of imaging probes that visualize the individual tumor situation.
AlleinstellungsmerkmalWe are open to any input from academic and industry partners looking for the de nition of novel targets or strati cation of existing ones for novel elds of application as well as using these pre-de ned molecular targets to develop high-end functional imaging applications using probes for positron emission tomography (PET) or single photon emission tomography (SPECT).
Clinical MALDIMALDI-MS is a highly sensitive and rapid analytical technique which is ideal for biomarker discovery & monitoring. MALDI-MS allows detection of a large numbers of molecules in tissues (“imaging”) or body uids (“liquid biopsy”).
AlleinstellungsmerkmalWe have a focus on the development, optimisation and use of Matrix-Assisted Laser Desorption/Ionisation (MALDI) mass spectrometry (MS) in diverse clinical areas (e.g. cancer, CVD, neuropathology, etc.).
Specifically we are developing methods and work ows for MALDI-MS imaging for the detection and characterisation of the immune cell distribution in cancer tissue and the detection and identi cation of biomarkers in blood (e.g. lipoproteins, extracellular vesicles, etc.).
Kontakt Wirtschaftsagentur Wien
Information and networking are co-funded by the European Fund for regional development as part of the „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ project. Additional information on the IWB/EFRE funding programme